Topic:

M&A

Latest Headlines

Latest Headlines

Pfizer and Sun snatch up sterile injectable companies to boost expertise and capacity

The sterile injectables business holds promise for drugmakers with the manufacturing capabilities to produce the difficult-to-make drugs. Deals announced Wednesday by Pfizer and Sun Pharma were proof positive of how companies think they can cash in on the generics piece of this sterile injectables market.

'Economic patriotism' could dampen biopharma's M&A boom

The fervor over American companies merging with overseas rivals to lower their tax rates has drawn the ire of the Obama Administration, possibly imperiling the so-called inversion deals that have become increasingly popular in biopharma.

Dublin-based Perrigo could be up next for a tax-inversion deal

OTC generics maker Perrigo could be the next tax-advantaged company in line for a buyout. And while Perrigo hasn't confirmed any M&A plans, speculation has been enough to send shares soaring.

Abbott CEO: 'I don't feel the pressure to invert'

Wall Street analysts took advantage of a conference call on Abbott's just-announced sale of its developed market generics business to ask about some of their favorite topics, future M&A and the recent onset of  tax inversion mania among life science companies. 

St. Jude shells out $200M for chronic pain therapy manufacturer NeuroTherm

St. Jude Medical signed on the dotted line to acquire interventional pain management therapy manufacturer NeuroTherm for approximately $200 million in cash, strengthening its foothold in the chronic pain market.

Abbott continues evolution toward devices, planning to sell generics portfolio for $5.3B

Following the $5.3 billion sale of Abbott Laboratories' developed market generic drugs business to Mylan, diagnostics and devices will account for the majority of the company's sales, while pharmaceuticals' contribution to company-wide sales will stand at about 15%, based on 2013 earnings.  

Riled by $84,000 Sovaldi, Senate panel digs into Gilead's Pharmasset buy

Add a new set of pricing foes for Gilead Sciences). A U.S. Senate committee has joined the forces arrayed against the company's breakthrough hepatitis C drug Sovaldi and its $84,000 price tag.

Shire finally comes to AbbVie's buyout table, thanks to $53B-plus bid

Look who's talking. After four takeover bids from AbbVie, target Shire is finally in discussions with the Illinois drugmaker. And those have yielded yet another improved offer--a $53.7 billion bid Shire says its board would back.

Shire and AbbVie inch closer to a deal after weekend getaway

There's a whiff of inevitability with AbbVie's quest for Shire, as the latter company has confirmed that the two have found an agreeable price, setting the stage for a potential merger worth about $53.7 billion.

Mylan beefs up outside the U.S. with $5.3B deal for Abbott drug business

Mylan has been hunting for a buy. Now, it's found one. The Pittsburgh-based generics specialist is buying a big chunk of Abbott Laboratories' drug business, in a stock swap worth $5.3 billion. With $2 billion in annual sales, the products would jack up Mylan's top line by almost 30%.